Safety Pharmacology - Risk Assessment QT Interval Prolongation and Beyond

Current regulatory guidelines for cardiac safety utilize hERG block and QT interval prolongation as risk markers. This strategy has been successful at preventing harmful drugs from being marketed, but criticized for leading to early withdrawal of potentially safe drugs. Here we collected a series of...

Full description

Bibliographic Details
Main Author: Stefano Morotti
Other Authors: Eleonora Grandi, Esther Pueyo, Blanca Rodriguez
Format: eBook
Language:English
Published: Frontiers Media SA 2018
Series:Frontiers Research Topics
Subjects:
Online Access:
Collection: Directory of Open Access Books - Collection details see MPG.ReNa
LEADER 02177nma a2200373 u 4500
001 EB001965614
003 EBX01000000000000001128516
005 00000000000000.0
007 cr|||||||||||||||||||||
008 210512 ||| eng
020 |a 978-2-88945-539-3 
020 |a 9782889455393 
100 1 |a Stefano Morotti 
245 0 0 |a Safety Pharmacology - Risk Assessment QT Interval Prolongation and Beyond  |h Elektronische Ressource 
260 |b Frontiers Media SA  |c 2018 
300 |a 1 electronic resource (385 p.) 
653 |a multi-scale modeling 
653 |a drug-induced arrhythmia 
653 |a Physiology / bicssc 
653 |a QT interval prolongation 
653 |a cardiotoxicity 
653 |a cardiac electrophysiology. 
700 1 |a Eleonora Grandi 
700 1 |a Esther Pueyo 
700 1 |a Blanca Rodriguez 
041 0 7 |a eng  |2 ISO 639-2 
989 |b DOAB  |a Directory of Open Access Books 
490 0 |a Frontiers Research Topics 
500 |a Creative Commons (cc), https://creativecommons.org/licenses/by/4.0/ 
024 8 |a 10.3389/978-2-88945-539-3 
856 4 0 |u https://www.frontiersin.org/research-topics/5662/safety-pharmacology---risk-assessment-qt-interval-prolongation-and-beyond  |7 0  |x Verlag  |3 Volltext 
856 4 2 |u https://directory.doabooks.org/handle/20.500.12854/58773  |z DOAB: description of the publication 
082 0 |a 612 
520 |a Current regulatory guidelines for cardiac safety utilize hERG block and QT interval prolongation as risk markers. This strategy has been successful at preventing harmful drugs from being marketed, but criticized for leading to early withdrawal of potentially safe drugs. Here we collected a series of articles presenting new technological and conceptual advances, including refinement of ex vivo and in vitro assays, screens and models, and in silico approaches reflecting the increasing effort that has been put forward by regulatory agencies, industry, and academia to try and address the need of a more accurate, mechanistically-based paradigm of proarrhythmic potential of drugs. This Research Topic is dedicated to the memory of Dr. J. Jeremy Rice, our wonderful friend and colleague.